sever
acut
respiratori
syndrom
sar
seriou
infecti
threat
public
health
creat
novel
trial
vaccin
evalu
potenc
attempt
gener
sar
inactiv
vaccin
use
sar
coronaviru
sarscov
strain
treat
formaldehyd
mix
al
oh
three
dose
vaccin
use
challeng
three
group
balbc
mice
found
mice
exhibit
specif
igm
day
igg
day
peak
titer
igg
day
lowdos
group
highdos
group
wherea
middledos
group
peak
day
day
igg
level
reach
plateau
neutral
assay
demonstr
antisera
could
protect
cell
sarscov
infect
analysi
antibodi
specif
reveal
mous
antisera
contain
mixtur
antibodi
specif
structur
protein
sarscov
furthermor
mous
antisera
confer
higher
amount
antibodi
protein
n
polypeptid
protein
find
suggest
inactiv
sarscov
could
preserv
antigen
inactiv
vaccin
stimul
mice
produc
high
level
antibodi
neutral
activ
result
also
suggest
polypeptid
origin
protein
n
might
potenti
target
gener
recombin
sar
vaccin
sever
acut
respiratori
diseas
unknown
etiolog
first
report
guangdong
provinc
peopl
republ
china
late
sequenti
broke
hong
kong
northern
america
earli
diseas
name
sever
acut
respiratori
syndrom
sar
novel
coronaviru
sar
coronaviru
sarscov
first
identifi
etiolog
pathogen
sar
sever
sarscov
genom
map
proteom
research
carri
achiev
pave
path
develop
safe
effect
sar
vaccin
number
studi
use
coronaviru
vaccin
demonstr
inactiv
vaccin
one
effect
method
protect
anim
coronaviru
includ
canin
coronaviru
infecti
bronchiti
viru
bovin
coronaviru
although
hostpathogen
relationship
immunopathogenesi
sarscov
fulli
understood
postul
may
feasibl
develop
inactiv
vaccin
sarscov
moreov
safeti
effect
inactiv
vaccin
human
also
demonstr
clinic
applic
vaccin
japanes
enceph
hemorrhag
fever
type
rabi
studi
perform
two
goal
mind
prepar
sar
inactiv
vaccin
ii
investig
whether
vaccin
could
stimul
anim
model
produc
neutral
antibodi
use
sarscov
isol
previous
prepar
trial
sar
inactiv
vaccin
data
immunogen
studi
suggest
vaccin
could
stimul
mice
produc
high
level
antibodi
could
protect
cell
sarscov
challeng
result
may
shed
light
develop
sar
vaccin
futur
sar
coronaviru
antibodi
ab
diagnost
kit
purchas
beij
bgigbi
biotech
hrpconjug
goat
antimous
igg
purchas
form
bethyl
laboratori
sar
ab
detect
type
kit
obtain
shanghai
health
digit
specif
pathogen
free
balbc
mice
weight
g
g
provid
first
militari
medic
univers
pla
sarscov
isol
oropharyng
swab
cantones
patient
live
amoy
garden
dna
sequenc
comparison
show
highli
homolog
similar
strain
report
includ
hku
us
urbani
titer
determin
tcid
ml
mu
method
largescal
cultiv
virus
inactiv
formaldehyd
day
c
purifi
gel
filtrat
treat
virus
mix
equival
volum
al
oh
adjuv
use
trial
sar
vaccin
balbc
mice
randomli
divid
three
group
n
mice
group
challeng
trial
vaccin
three
dose
lowdos
equival
tcid
sarscov
middledos
tcid
highdos
tcid
group
mice
challeng
three
time
day
control
group
inject
nacl
time
mice
bled
tail
vein
day
igm
igg
specif
sarscov
mice
sera
determin
indirect
enzymelink
immunosorb
assay
elisa
brief
polystyren
plate
corn
costar
coat
lyse
sarscov
incub
serial
twofold
dilut
sera
color
hrpconjug
ab
ophenylendiamin
sigma
maximum
dilut
serum
display
posit
reaction
defin
titer
sarscov
specif
ab
chemiluminesc
enzym
immunoassay
cleia
appli
analyz
strength
mous
ab
bind
sarscov
structur
protein
seven
recombin
protein
polypeptid
sarscov
n
immobil
solid
matrix
mous
antisera
incub
immobil
protein
follow
enzymeconjug
antimic
igg
chemiluminesc
substanc
light
signal
reaction
detect
chip
reader
shanghai
health
digit
pn
valu
ratio
signal
strength
antisera
neg
control
calcul
use
instrument
bound
softwar
complet
orf
protein
n
sarscov
clone
plasmid
produc
histag
fuse
protein
escherichia
coli
spike
gene
divid
four
fragment
nt
nt
nt
nt
recombin
polypeptid
produc
use
strategi
protein
n
polypeptid
produc
gst
pentrahi
doubletag
fusion
protein
purif
seven
recombin
polypeptid
analyz
sdspage
confirm
singl
band
size
ident
deduc
amino
acid
sequenc
data
shown
antigen
recombin
polypeptid
confirm
western
blot
analysi
use
serum
convalesc
sar
patient
neutral
antibodi
determin
inhibit
cytopath
effect
cpe
defin
morpholog
chang
cellular
death
mediat
sarscov
cell
monolay
describ
brief
cell
cellsml
cultur
microtit
plate
pretreat
serumviru
mixtur
contain
equival
volum
dilut
serum
sarscov
tcid
ml
inocul
microtit
plate
mlwell
incub
day
c
co
atmospher
cpe
well
record
everi
day
maximum
dilut
serum
complet
prevent
cpe
testwel
defin
titer
serum
viru
control
serum
show
complet
cpe
fig
show
product
igm
ab
three
group
mice
inject
differ
dose
vaccin
specif
igm
ab
level
mice
sera
express
od
dilut
sera
found
igm
ab
plasma
becam
detect
day
increas
sharpli
day
vaccinechalleng
group
day
level
igm
ab
remain
stabl
reach
plateau
day
igm
ab
level
start
declin
note
level
igm
differ
group
gener
correl
dose
use
immun
profil
igg
ab
product
respons
sar
vaccin
shown
fig
igg
ab
appear
mice
sera
day
reach
peak
day
middledos
group
day
went
platform
phase
day
peak
titer
igg
lowdos
group
middledos
group
highdos
group
respect
day
titer
three
group
respect
compar
titer
among
differ
group
found
level
igg
ab
exhibit
clear
correl
inocul
dose
except
day
gener
igg
titer
highdos
group
twothreefold
higher
lowdos
group
seven
recombin
polypeptid
origin
four
sarscov
structur
protein
n
appli
determin
specif
strength
ab
mice
antisera
found
antisera
contain
ab
specif
seven
antigen
howev
gener
ab
specif
protein
n
tend
stronger
protein
fig
fig
specif
rel
strength
antibodi
specif
sarscov
structur
protein
mice
sera
day
protein
n
sarscov
produc
fulllength
protein
recombin
escherichia
coli
protein
divid
four
fragment
seven
recombin
polypeptid
immobil
solid
matrix
chemiluminesc
enzym
immunoassay
cleia
appli
analyz
specif
rel
strength
antibodi
antisera
pn
valu
ratio
signal
strength
antisera
control
sera
list
fig
kinet
chang
neutral
ab
mice
sera
day
day
maximum
dilut
sera
sampl
abl
protect
half
testwel
cpe
defin
neutral
titer
transform
neg
log
display
graph
determin
protect
strength
antisera
obtain
mice
day
perform
neutral
assay
use
cultur
cell
found
antisera
show
variou
abil
inhibit
cytopath
effect
mediat
sarscov
cell
fig
day
neutral
ab
remain
plateau
peak
titer
three
vaccineimmun
group
respect
day
neutral
titer
lowdos
group
middledos
group
highdos
group
studi
demonstr
sar
inactiv
vaccin
stimul
balbc
mice
produc
high
level
specif
ab
neutral
activ
comparison
convalesc
sar
patient
ab
level
neutral
activ
immun
mice
time
higher
curv
igg
ab
mice
indic
specif
ab
remain
high
level
long
period
result
confirm
feasibl
efficaci
sar
inactiv
vaccin
also
perform
similar
experi
use
speci
rat
rabbit
hors
monkey
also
confirm
effect
vaccin
wang
et
al
prepar
specif
analysi
reveal
igg
ab
mice
antisera
mixtur
ab
specif
structur
protein
sarscov
recent
studi
report
dna
vaccin
target
protein
n
could
induc
sever
event
includ
product
specif
ab
andor
activ
cytotox
lymphocyt
protect
immun
mice
highli
attenu
modifi
vaccinia
viru
ankara
contain
gene
encod
fulllength
sarscov
also
prove
abl
induc
protect
immun
mice
show
first
time
ab
specif
protein
n
stronger
structureprotein
specif
ab
induc
inactiv
vaccin
sui
et
al
recent
report
potent
neutral
mcab
epitop
locat
within
ntermin
amino
acid
protein
accord
observ
found
level
ab
predomin
mice
sera
result
antigen
analysi
sarscov
structur
protein
propos
protein
andor
n
may
potenti
subunit
effect
vaccin
sarscov
like
hiv
rna
viru
errorpron
replic
mechan
escap
mutat
respons
immun
system
observ
select
point
mutat
known
respons
major
shift
pathogen
well
tissu
specif
bovin
coronaviru
mutat
genom
sarscov
recent
describ
mutat
may
hamper
develop
effect
vaccin
sarscov
howev
neutral
test
antisera
induc
sar
inactiv
vaccin
found
antisera
could
neutral
cpe
sarscov
strain
also
strain
anoth
sarscov
isol
femal
patient
belong
superspread
event
guangdong
provinc
find
signific
differ
two
strain
term
neutral
titer
data
shown
crossprotect
strengthen
urgenc
evalu
protect
immun
inactiv
vaccin
primat
futur
immun
respons
coronavirus
suggest
cellmedi
humor
immun
contribut
longterm
protect
inactiv
vaccin
usual
induc
weak
cellmedi
immun
also
observ
signific
chang
subset
lymphocyt
vaccinechalleng
mice
data
shown
latest
studi
found
ab
alon
could
prevent
replic
sar
coronaviru
lung
mice
observ
suggest
weak
sar
inactiv
vaccin
might
overcom
advantag
vaccin
produc
current
studi
